ACE-031, also written ACVR2B, is a fusion protein based on the activin receptor type 2B. It works as a decoy receptor, capturing myostatin and related molecules before they reach cells. Sold as research material, not as a medicine.
Bio-Peptide, 10 mg
320,00 złAdd to cart3 in stock (can be backordered)
Genheal, 10 mg
300,00 złAdd to cartAvailable on backorder
Nouveaux Ltd., 10 mg
420,00 złAdd to cart4 in stock (can be backordered)
What is in the vial
All three manufacturers supply 10 mg vials. A 10 mg vial with 2 ml of bacteriostatic water gives 5 mg per millilitre; the arithmetic is in the guide on reconstitution. These are the most expensive vials in the muscle group, and the reason is the molecule: a fusion protein is a larger and more demanding thing to manufacture than a short peptide, which also makes the batch certificate more worth reading than usual.
Why its clinical programme was closed
ACE-031 is the one molecule in this group that reached clinical trials, in boys with Duchenne muscular dystrophy. The trials were halted on 21 April 2011 on safety grounds, and on 2 May 2013 the companies closed the programme without restarting it.
Some participants developed nosebleeds and bleeding gums, along with small dilated blood vessels in the skin, which resolved after the drug was stopped. Those vascular effects were linked to blocking BMP9 and BMP10 signals, which matter for normal blood vessel function.
What that means for a buyer
It means this molecule has more human safety data than most things in this catalogue, and that data is the reason its development stopped. That is worth knowing before rather than after. The context is in the muscle peptides guide and the comparison with the other blocker in follistatin 344 and ACE-031.
The mechanism is also the reason for the side effects, not an accident of dosing: a decoy receptor that captures myostatin captures related signalling molecules too, and two of them are needed for normal blood vessels.
Status
Not approved anywhere. No myostatin blocker has been approved for muscle growth since the programme closed. We publish no dosing schedules; the doses used in the halted trials belong to a supervised clinical setting that no longer exists.
Handling and verification
Supplied as lyophilised powder. Storage rules change once it is dissolved: see storage. Check the code under the hologram and the batch certificate as described in check your product. We ship within Poland and abroad; outside Poland the cost is quoted individually, depending on weight and destination country. Details: shipping and payments.
Questions
Why were the ACE-031 trials stopped?
On safety grounds, in April 2011. Participants developed nosebleeds, bleeding gums and small dilated blood vessels in the skin, which resolved after the drug was stopped.
Were those effects a dosing accident?
They were linked to blocking BMP9 and BMP10 signals, which the mechanism does by design, so they follow from how the molecule works.
Has any myostatin blocker been approved since?
No. None has been approved for muscle growth since that programme closed in 2013.
Is it allowed in sport?
No. This is exactly the kind of mechanism anti-doping rules cover.